Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 55, Issue 1, pp 33–38 | Cite as

Phase I study of green tea extract in patients with advanced lung cancer

  • Scott A. Laurie
  • Vincent A. MillerEmail author
  • Stefan C. Grant
  • Mark G. Kris
  • Kenneth K. Ng
Original Article

Abstract

Purpose

Epidemiologic studies suggest that consumption of green tea may have a protective effect against the development of several cancers. Preclinical studies of green tea and its polyphenolic components have demonstrated antimutagenic and anticarcinogenic activity, and inhibition of growth of tumor cell lines and animal tumor models, including lung cancer. Green tea may also have chemopreventive properties, and enhancement of cytotoxicity of chemotherapeutic agents has been demonstrated. This trial was designed to determine the maximum tolerated dose (MTD) of green tea extract (GTE) in patients with advanced lung cancer.

Methods

A total of 17 patients with advanced lung cancer were registered to receive once-daily oral dosing of GTE at a starting dose of 0.5 g/m2 per day, with an accelerated dose-escalation scheme.

Results

On this schedule, the MTD of GTE was 3 g/m2 per day, and at this dose, GTE was well tolerated with no grade 3 or 4 toxicity seen. Dose-limiting toxicities were diarrhea, nausea and hypertension. No objective responses were seen in this trial. Seven patients had stable disease ranging from 4 to 16 weeks; no patient remained on therapy longer than 16 weeks due to the development of progressive disease.

Conclusions

This study suggests that while relatively nontoxic at a dose of 3 g/m2 per day, GTE likely has limited activity as a cytotoxic agent, and further study of GTE as a single-agent in established malignancies may not be warranted. Further studies should focus on the potential chemopreventive and chemotherapy-enhancing properties of GTE.

Keywords

Green tea Clinical trial Phase I Lung cancer 

Abbreviations

GTE

Green tea extract

EGCG

Epigallocatechin gallate

EGC

Epigallocatechin

ECG

Epicatechin-3-gallate

EC

Epicatechin

DLT

Dose-limiting toxicity

MTD

Maximum tolerated dose

NSCLC

Non-small cell lung cancer

MDACC

M.D. Anderson Cancer Center

Notes

Acknowledgement

This study was supported, in part, by Ito En, Ltd.

References

  1. 1.
    Ahmad N, Feyes DK, Nieminen AL, Agarwl R, Mukhtar H (1997) Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cell. J Natl Cancer Inst 89:1881–1886CrossRefPubMedGoogle Scholar
  2. 2.
    Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684–692PubMedGoogle Scholar
  3. 3.
    Fujiki H, Suganuma M, Okabe S, Komori A, Eisaburo S, Sueoka N, Kozu T, Sakai Y (1996) Japanese green tea as a cancer preventive in humans. Nutr Rev 54:S67–S70PubMedGoogle Scholar
  4. 4.
    Gao YT, McLaughlin JK, Blot WJ, Ji BT, Dai Q, Fraumeni JF Jr (1994) Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 86:855–858PubMedGoogle Scholar
  5. 5.
    Imai K, Suga K, Nakachi K (1997) Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 26:769–775CrossRefPubMedGoogle Scholar
  6. 6.
    Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, Blot WJ, Fraumeni JF Jr (1997) Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 70:255–258CrossRefPubMedGoogle Scholar
  7. 7.
    Komori A, Yatsunami J, Okabe S, Abe S, Hara K, Suganuma M, Kim SJ, Fujiki H (1993) Anticarcinogenic activity of green tea polyphenols. Jpn J Clin Oncol 23:186–190PubMedGoogle Scholar
  8. 8.
    Okabe S, Suganuma M, Hayashim M, Sueoka E, Komori A, Fujiki H (1997) Mechanisms of growth inhibition of human lung cancer cell line, PC-9, by tea polyphenols. Jpn J Cancer Res 88:639–643PubMedGoogle Scholar
  9. 9.
    Pianetti S, Guo S, Kavanagh KT, Sonenshein GE (2002) Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 62:652–655PubMedGoogle Scholar
  10. 10.
    Pisters KMW, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS (2001) Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19:1830–1838PubMedGoogle Scholar
  11. 11.
    Sadzuka Y, Sugiyama T, Hirota S (1998) Modulation of cancer chemotherapy by green tea. Clin Cancer Res 4:153–156PubMedGoogle Scholar
  12. 12.
    Setiawan VW, Zhang ZF, Yu GP, Lu QY, Li YL, Lu ML, Wang MR, Guo CH, Yu SZ, Kurtz RC, Hsieh CC (2001) Protective effect of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer 92:600–604CrossRefPubMedGoogle Scholar
  13. 13.
    Suga K, Imai K, Sueoka N, Nakachi K (1998) Phase I clinical trial with green tea tablets in a Japanese healthy population. Cancer Prev Int 3:79–88Google Scholar
  14. 14.
    Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H (1999) Synergistic effects of (−)-epigallocatechin gallate with (−)-epicatechin, sulindac or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59:44–47PubMedGoogle Scholar
  15. 15.
    Wang ZY, Huang MT, Ferraro T, Wong CQ, Lou YR, Reuhl KR, Iatropoulos MJ, Yang CS, Conney AH (1992) Inhibitory effect of green tea in the drinking water on tumorigenesis by ultraviolet light and 12-O-tetradecanolyphorbol-13-acetate in the skin of SKH-1 mice. Cancer Res 52:1162–1170PubMedGoogle Scholar
  16. 16.
    Wang ZY, Hong JY, Huang MT, Reuhl KR, Conney AH, Yang CS (1992) Inhibition of N-nitrosodiethylamine- and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mice by green tea and black tea. Cancer Res 52:1943–1947PubMedGoogle Scholar
  17. 17.
    Wang ZY, Huang MT, Ho CT, Chang R, Ma W, Ferraro T, Reuhl KR, Yang CS, Conney AH (1992) Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 52:6657–6665PubMedGoogle Scholar
  18. 18.
    Xu Y, Ho CT, Amin SG, Han C, Chung FL (1992) Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res 52:3875–3879PubMedGoogle Scholar
  19. 19.
    Yoshizawa S, Horiuchi T, Fujiki H, Yoshida T, Okuda T, Sugimura T (1987) Antitumor promoting activity of (−)-epigallocatechin gallate, the main constituent of “tannin” in green tea. Phytother Res 1:44–47Google Scholar
  20. 20.
    Yu GP, Hsieh CC, Wang LY, Yu SZ, Li XL, Jin TH (1995) Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai, China. Cancer Causes Control 6:532–538PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Scott A. Laurie
    • 1
  • Vincent A. Miller
    • 1
    Email author
  • Stefan C. Grant
    • 1
  • Mark G. Kris
    • 1
  • Kenneth K. Ng
    • 1
  1. 1.Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations